These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 17014005

  • 21. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 22. Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies.
    Angel K, Provan SA, Hammer HB, Mowinckel P, Kvien TK, Atar D.
    Fundam Clin Pharmacol; 2011 Aug; 25(4):511-7. PubMed ID: 20825487
    [Abstract] [Full Text] [Related]

  • 23. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis.
    da Silva BS, Bonfá E, de Moraes JC, Saad CG, Ribeiro AC, Gonçalves CR, de Carvalho JF.
    Biologicals; 2010 Sep; 38(5):567-9. PubMed ID: 20638299
    [Abstract] [Full Text] [Related]

  • 24. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC, Chung SJ, Park YB, Lee SK.
    Scand J Rheumatol; 2008 Sep; 37(3):173-8. PubMed ID: 18465450
    [Abstract] [Full Text] [Related]

  • 25. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS, Nordvåg BY, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [Abstract] [Full Text] [Related]

  • 26. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis.
    Saiki O, Takao R, Naruse Y, Kuhara M, Imai S, Uda H.
    J Rheumatol; 2007 Oct; 34(10):1997-2004. PubMed ID: 17787045
    [Abstract] [Full Text] [Related]

  • 27. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
    Flendrie M, Creemers MC, van Riel PL.
    Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
    [Abstract] [Full Text] [Related]

  • 28. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis.
    García-Gómez C, Nolla JM, Valverde J, Gómez-Gerique JA, Castro MJ, Pintó X.
    J Rheumatol; 2009 Jul; 36(7):1365-70. PubMed ID: 19369465
    [Abstract] [Full Text] [Related]

  • 29. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [Abstract] [Full Text] [Related]

  • 30. Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study.
    Filippatos TD, Derdemezis CS, Voulgari PV, Tsimihodimos V, Elisaf MS, Tselepis AD, Drosos AA.
    Scand J Rheumatol; 2013 May; 42(3):169-75. PubMed ID: 23311768
    [Abstract] [Full Text] [Related]

  • 31. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.
    Gengenbacher M, Sebald HJ, Villiger PM, Hofstetter W, Seitz M.
    Ann Rheum Dis; 2008 May; 67(5):620-4. PubMed ID: 17720725
    [Abstract] [Full Text] [Related]

  • 32. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA.
    Ann Rheum Dis; 2005 May; 64(5):765-6. PubMed ID: 15458960
    [Abstract] [Full Text] [Related]

  • 33. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
    Popa C, Netea MG, Radstake T, Van der Meer JW, Stalenhoef AF, van Riel PL, Barerra P.
    Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
    [Abstract] [Full Text] [Related]

  • 34. Significance of dyslipidaemia in patients with heart failure of unexplained aetiology.
    Skwarek M, Bilińska ZT, Mazurkiewicz Ł, Grzybowski J, Kruk M, Kurjata P, Piotrowski W, Ruzyłło W.
    Kardiol Pol; 2008 May; 66(5):515-22, discussion 523-4. PubMed ID: 18537059
    [Abstract] [Full Text] [Related]

  • 35. Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab.
    Braun J, van der Heijde D, Doyle MK, Han C, Deodhar A, Inman R, de Vlam K, Burmester GR, Van den Bosch F, Xu S, Visvanathan S, Rahman MU.
    Arthritis Rheum; 2009 Aug 15; 61(8):1032-6. PubMed ID: 19644896
    [Abstract] [Full Text] [Related]

  • 36. The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass.
    Yazici S, Yazici M, Erer B, Erer B, Calik Y, Bulur S, Ozhan H, Ataoglu S.
    Platelets; 2010 Aug 15; 21(2):126-31. PubMed ID: 20050759
    [Abstract] [Full Text] [Related]

  • 37. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients.
    Morris SJ, Wasko MC, Antohe JL, Sartorius JA, Kirchner HL, Dancea S, Bili A.
    Arthritis Care Res (Hoboken); 2011 Apr 15; 63(4):530-4. PubMed ID: 21452265
    [Abstract] [Full Text] [Related]

  • 38. Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD.
    Siamopoulos KC, Gouva C, Katopodis KP, Tzallas C, Nikolopoulos P, Papavasiliou EC, Tselepis AD.
    Am J Kidney Dis; 2006 Aug 15; 48(2):242-9. PubMed ID: 16860190
    [Abstract] [Full Text] [Related]

  • 39. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.
    Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Combe B, Durbach A, Sibilia J, Dougados M, Mariette X.
    Arthritis Rheum; 2003 Jul 15; 48(7):2019-24. PubMed ID: 12847696
    [Abstract] [Full Text] [Related]

  • 40. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
    Odai T, Matsunawa M, Takahashi R, Wakabayashi K, Isozaki T, Yajima N, Miwa Y, Kasama T.
    J Rheumatol; 2009 Jun 15; 36(6):1158-65. PubMed ID: 19369458
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.